Intellia Therapeutics, Inc. (NTLA) shares ended the last trading session 29.8% higher at $16.11. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.6% gain over the past four weeks.The stock rallied after the company announced that it has completed enrollment in the pivotal phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonvo-z) for treating patients with hereditary angioedem ...